2 years after merger, Syneos Health 'exploring a sale': report

Nasdaq
CRO Syneos Health's shares shot up on the news it's looking for a sale, though they are down due to coronavirus fears. (Nasdaq)

It’s been just over two years since INC Research and inVentiv came together in a $7.4 billion merger and rebranded as Syneos Health. Now, it’s looking for a sale.

That’s according to “people familiar with the matter” speaking anonymously to Reuters this week, who add that the North Carolina CRO is working with investment bank Centerview Partners “on soliciting acquisition offers from other companies and private equity firms.”

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

RELATED: INC Research/inVentiv Health rebrands as Syneos Health

The CRO had been trading down—like almost every public company due to the coronavirus volatility—but was up by $10 a share on the Reuters report March 9, although it was back in the red in trading Tuesday. Its market cap is around $6.4 billion.

The CRO was not commenting on the story.

Suggested Articles

The Tel Aviv-based VC firm focused on digital health has closed a new fund totaling $170 million, with plans to expand to the Asia Pacific region.

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.